Live Feeds
● TRACKER Updated 7d ago · 5 sources tracked

Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test

Novartis shares plummeted 10 percent, heading for their worst day on record, after a crucial phase 3 clinical trial failure. The failed drug served as the centerpiece of a 12 billion dollar Avidity buyout. This setback represents the second pipeline failure for the pharmaceutical major within a single week, adding to a total of three recent drug trial setbacks. Meanwhile, Dyne Therapeutics shares fell 31 percent in premarket trading. The trial failure serves as a cautionary tale for pharmaceutical mergers and acquisitions across the industry.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (5)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Novartis shares plummeted 10 percent, heading for their worst day on record after three drug trial setbacks.
  • ✓ The failed drug trial was the centerpiece of a 12 billion dollar Avidity buyout.
  • ✓ Novartis shares sank on a second pipeline setback during the week.
  • ✓ Dyne Therapeutics shares fell 31 percent premarket.
🛡️ Source Corroboration: 5 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Novartis stock plummeted following the failure of a crucial phase 3 trial tied to a major acquisition.

Live updates

  1. Novartis Plummets as Avidity Buyout Drug Flunks Phase 3 Test

    Novartis shares plummeted 10 percent, heading for their worst day on record, after a crucial phase 3 clinical trial failure. The failed drug served as the centerpiece of a 12 billion dollar Avidity buyout. This setback represents the second pipeline failure for the pharmaceutical major within a single week, adding to a total of three recent drug trial setbacks. Meanwhile, Dyne Therapeutics shares fell 31 percent in premarket trading. The trial failure serves as a cautionary tale for pharmaceutical mergers and acquisitions across the industry.

    Why it matters

    Pharmaceutical companies frequently rely on multi-billion-dollar acquisitions to replenish aging drug pipelines and secure future revenue streams. When a headline asset fails a pivotal late-stage trial, the financial fallout hits the acquiring company's stock price immediately. This incident highlights the high stakes and inherent clinical risks associated with large-scale pharma buyout strategies.

    What is confirmed

    • Novartis shares plummeted 10 percent, heading for their worst day on record after three drug trial setbacks.
    • The failed drug trial was the centerpiece of a 12 billion dollar Avidity buyout.
    • Novartis shares sank on a second pipeline setback during the week.
    • Dyne Therapeutics shares fell 31 percent premarket.

    Still unconfirmed

    • There was no catalyst confirmed for the premarket fall in Dyne Therapeutics shares.

    What to watch next

    • Updates from Novartis on the financial restructuring or future strategy regarding the Avidity acquisition
    • Further market reaction to the pharmaceutical merger and acquisition cautionary outcomes
    Sources used for this update (5)
    1. CNBC — Pharma major Novartis plummets 10%, heading for worst day on record after three drug trial setbacks
    2. Reuters — Novartis shares sink on second pipeline setback this week
    3. Fierce Biotech — Novartis’ centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
    4. finance.yahoo.com — Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed
    5. wsj.com — Novartis Trial Failure Serves as Cautionary Tale for Pharma M&A
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community